Qiagen (QGEN) said Monday it expanded its digital PCR technology network with updated gene expression tools and automated analysis features to support broader adoption in the sector.

The company plans to introduce advanced testing assays later this year alongside a high multiplex kit capable of analyzing up to 12 RNA targets simultaneously, the company said.

The group expanded its cell and gene therapy quality control offerings to cover additional host-cell systems while partnering with Hamilton to automate laboratory processes, Qiagen said.

The update introduces an evaluation program called QIAcuity Software 3.5, designed to standardize data interpretation and automated reporting, it said.